Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lane, S. E.
Right arrow Articles by Watts, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lane, S. E.
Right arrow Articles by Watts, R. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 328-332
© 2000 British Society for Rheumatology

Report

Vasculitis—aims of therapy Meeting Report, Cambridge, 10–11 September 1999

S. E. Lane and R. A. Watts1,

Norfolk and Norwich Hospital, Norwich and
1 Ipswich Hospital, Ipswich and School of Health, University of East Anglia, Norwich, UK


   Introduction
 
The meeting opened with the announcement of the tragic death shortly before the meeting of Dr Martin Lockwood, a member of the organizing committee. Sir Keith Peters gave a tribute to Martin Lockwood and dedicated the meeting to his memory.

Charles Pusey (London, UK) introduced the first session by asking whether enough is known about the pathogenesis of systemic vasculitis to identify ‘targets of therapy’ and reviewed current knowledge of genetic and environmental factors together with cellular and cytokine mediators of inflammation in vasculitis. He suggested several approaches to improving therapy by modifying standard drug regimes, developing newer agents such as mycophenolate mofetil, biological agents and gene therapy. Successful clinical and animal studies have shown promising routes for the modulation of the immune and inflammatory response. T-cell activation has been targeted in several ways in animal models, including monoclonal antibodies (Mab) against CD4, CD8, interleukin-2 (IL-2) receptors (IL-2R), T-cell receptors, . . . [Full Text of this Article]


   Notes
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?